Center of Excellence for Natural Product Drug interaction Research (U54, Clinical Trial Required)

The summary for the Center of Excellence for Natural Product Drug interaction Research (U54, Clinical Trial Required) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Center of Excellence for Natural Product Drug interaction Research (U54, Clinical Trial Required): The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for a Center of Excellence for Natural Product Drug Interaction Research to provide leadership in the study of natural product drug interactions. The ultimate goals of this program are to 1) clearly establish the clinical relevance of pharmacokinetic interactions from a select number of natural products, and 2) provide guidance and leadership to the broader research community on how best to research metabolism mediated drug interactions involving complex natural products. The Center will 1) identify, prioritize, source and characterize three to five natural products with potential to exhibit clinically significant interactions with commonly used medications; 2) perform all necessary preclinical work to characterize the interaction potential of the natural products including identifying the key mediators of any pharmacokinetic interaction as well as the mechanism(s) and magnitude of that interaction; 3) if warranted based on preclinical work, conduct rigorously designed clinical studies of these natural products to provide definitive data regarding the magnitude of any interaction in humans; 4) develop and maintain a repository for the data and methodology resources generated by this project as well as data generated by other researchers (especially the R21 grants funded through the companion RFA AT-20-001) regarding pharmacokinetic interactions involving natural products; and 5) provide ongoing guidance and leadership to the relevant research communities regarding how best to conduct research on pharmacokinetic natural product drug interactions; thereby facilitating better design of future research and ultimately better decisions regarding the concomitant use of medications and natural products.
Federal Grant Title: Center of Excellence for Natural Product Drug interaction Research (U54, Clinical Trial Required)
Federal Agency Name: National Institutes of Health (HHS-NIH11)
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-AT-20-002
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.213
CFDA Descriptions: Information not provided
Current Application Deadline: November 24th, 2019
Original Application Deadline: November 24th, 2019
Posted Date: July 23rd, 2019
Creation Date: July 23rd, 2019
Archive Date: December 30th, 2019
Total Program Funding: $2,250,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards: 1
Cost Sharing or Matching: No
Last Updated: July 23rd, 2019
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Link to Full Grant Announcement
Grant Announcement Contact
NIH OER Webmaster
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants
Preclinical Screening for Natural Product Drug Interactions (Clinical Trial Not Allowed, R...
"HEAL Initiative: Limited Competition: Resource Coordinating Center for Pragmatic and Impl...
Limited Competition: Interdisciplinary Complementary and Integrative Health Clinical Resea...
Exploratory Research for Technology Development (R21 - Clinical Trial Not Allowed)
Focused Technology Research and Development (R01 - Clinical Trial Not Allowed)
Probiotics for Pediatric Illnesses
Cam Practitioner Research Education Project Grant Partnership
Complementary and Alternative Medicine Career Transition Award (K22)
More Grants from the National Institutes of Health
Limited Competition: AIDS Malignancy Consortium (AMC) (UM1 Clinical Trials Required)
Advancing Sustained/Extended Release for HIV Prevention (A-SER) (R01 Clinical Trial Not Al...
Resource-Related Research Projects for Development of Animal Models and Related Materials ...
Tailoring Interventions to Improve Preventive Health Service Use (R61/R33 Clinical Trial R...
Social Epigenomics Research Focused on Minority Health and Health Disparities (R01-Clinica... is not endorsed by, or affiliated with, any government agency. Copyright ©2019